Sun Pharma receives DCGI approval to initiate clinical trail with Nafamostat Mesilate in Covid-19 patients
Capital MarketSun Pharmaceuticals Industries has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan
for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
